Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Receivables (2025)

Crescent Biopharma (CBIO) has disclosed Receivables for 2 consecutive years, with $18.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables changed N/A to $18.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.0 million, a N/A change, with the full-year FY2025 number at $18.0 million, changed N/A from a year prior.
  • Receivables was $18.0 million for Q4 2025 at Crescent Biopharma, down from $20.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $18.0 million in Q4 2025 to a low of $18.0 million in Q4 2025.